A long-term follow-up of botulinum toxin A in cervical dystonia

Authors: Mohammadi, B.1; Buhr, N.1; Bigalke, H.2; Krampfl, K.1; Dengler, R.1; Kollewe, K.1

Source: Neurological Research, Volume 31, Number 5, June 2009 , pp. 463-466(4)

Publisher: Maney Publishing

Buy & download fulltext article:

OR

Price: $48.00 plus tax (Refund Policy)

Or sign up for a free trial

Abstract:

Objective: Cervical dystonia (CD) is the most common form of adult-onset focal dystonia, and botulinum toxin A (BoNT-A) has become the first-line treatment for this condition.

Methods: In this work, we present data of 207 CD patients treated with BoNT-A for 6.7 ± 3.5 years. One hundred and sixty-three patients were treated with Dysport (mean dose, 389 ± 144 U) and 44 with Botox (mean dose, 145 ± 44 U).

Results: The mean clinical benefit, based on a 0–3 scale (0=no effect, 1=slight, 2=moderate and 3=marked improvement) was similar for Dysport (2.5 ± 0.3) and Botox (2.2 ± 0.4). Adverse events were mild and similar for both products. Fewer than 2% of the patients developed neutralizing antibodies.

Discussion: These data confirm the efficacy and safety of BoNT-A treatment in CD over an extended period of up to 14 years.

Keywords: CERVICAL DYSTONIA; BOTULINUM TOXIN; LONG-TERM FOLLOW-UP

Document Type: Research Article

DOI: http://dx.doi.org/10.1179/174313209X405137

Affiliations: 1: Department of Neurology and Clinical Neurophysiology, Hannover Medical School, Hannover, Germany 2: Department of Toxicology, Hannover Medical School, Hannover, Germany

Publication date: 2009-06-01

More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page